Antonio Rozzi, MD
Medical Oncology Unit
Istituto Neurotraumatologico Italiano Grottaferrata (Rome)
1998: Graduated cum Laude in 1998 at University of Rome “ Sapienza”. From November 1998 to November 2002: fellowship training in Medical Oncology at Experimental Medicine Department of University of Rome “Sapienza”. November 2002: Graduated cum Laude in Medical Oncology (II° School of Clinical Oncology of University of Rome “Sapienza”). From 1998 to 2002 actively involved in a regional home-care programme for terminally-ill cancer patients. From 2002 consultant oncologist at Clinical Oncology Unit of Istituto Neurotraumatologico Italiano of Grottaferrata (Rome). From 2010 this unit was chosen by European Society of Medical Oncology (ESMO) as designated center of Integrated Oncology and Palliative Care. Author or Co-author of 23 articles published in national and international medical journals. Author or Co-author of 47 abstracts presented at national and international conferences.
His research interests include: medical treatment of solid tumors, palliative care services and supportive care in oncology.
Dr. Rozzi was Invited speaker in several national conferences and courses. From 2011 invited teacher at School of Nursing of University of Rome “Tor Vergata”. From 2012 he served as the Editorial Board Member of “Journal of Palliative Care and Medicine”. From September 2013 member of Editorial Board of “American Journal of Nursing Research”, “Journal of Cancer Research and Treatment”, “Cancer Studies: Open Access”, “Palliative Medicine and Nursing: Open Access”.
1.Bianco V , Rozzi A, Terenzi S, et al. The prognostic factors in cancer patients with the disease in an advanced phase. Minerva Medica. 1999; 90(7/8): 242-244.
2.Longo F, Mansueto G, Poggi A, et al. Marchei Acute arterial thrombosis in a patient with small cell lung cancer after a cycle of chemotherapy with cisplatin and etoposide. Tumori. 1999; 85: n3.
3.Bianco V, Rozzi A, Girolamo BG, et al. GianniLa medical treatment of pain in Oncology Chapter 16 dellOpera Paul Marchei entitled. Medicina Oncologica. 2000.
4.Bianco V, Rozzi A, Gemma D, et al. Neoadjuvant chemotherapy in locally advanced gastric cancer.Minerva Medica. 2001; 92(1(4)): 1-6.
5.Bianco V, Rozzi A, Gemma D, et al. Role of chemotherapy in colorectal neoplasms dellanziano.Minerva Medica. 2002; 93 (1(4)): 87-99.
6.Rozzi A, Salerno M, Gemma D, et al. Volunteer and home care of the cancer patient terminal. Minerva Medica. 2002; 93(4): 127-130.
7.Bianco V, Rozzi A, Tonini G, et al. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV Non Small Cell Lung Cancer (NSCLC) a phase II study. Anticancer Research. 2002; 22: 3053-3056.
8.Lanzetta G, Campanella C, Rozzi A, et al. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme phase II clinical trial. Anticancer Research. 2003; 23: 5159-5164.
9.Rozzi A, Nardoni C, Lanzetta G. Second-line chemotherapy with weekly docetaxel in elderly patients with non-small cell lung cancer (CPNAPC) preliminary results of a phase II study.Scenari rivista di oncologia pratica e sperimentale. 2005; 4(5): 75-78.
10. Rozzi A, Lanzetta G, Bove F, et al. Chemotherapy in bone metastases.Realta Medica. 2000; 3: 51-54.
11.Costa AM,Lanzetta G,Rozzi A,et al. Role of radiotherapy fractionation of the dose in the treatment of bone metastases. Realta Medica. 2000; 352-55.
12.Lanzetta G, Rozzi A, Nardoni C, et al. Oncology rehabilitation goals and objectives.Realta Medica. 2000; 4: 7-22.
13.Rozzi A, Nardoni C, Corona M, et al. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide a phase II study. Support Care Cancer. 2010. doi: 10.1007/s00520-010-0893-y
14.Rozzi A, Nardoni C, Corona M,et al. Weekly regimen of paclitaxel and carboplatin as first-line chemotherapy in elderly patients with stage IIIB-IV non- small-cell lung cancer (NSCLC) results of a phase II study.J Chemother. 2010; 22(6): 419-423.
15.Rozzi A, Bordin F, Scirocchi R, et al. Prevalence and intensity of pain in terminally-ill cancer patients at admission in palliative care center a mono-institutional descriptive analysis. Recenti Progr Med. 2011; 102: 114-116.
16. Rozzi A, Salerno M, Bordin F, et al. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the urothelial tract results of a phase II study. Med Oncol. 2011; 28(Supp 1): S426-S432. doi: 10.1007/s12032-010-9749-z
17. Rozzi A, Scirocchi R, Fava A, et al. Pain assessment in terminally-ill cancer patients on admission in hospice and its modification after the first three days of care. A moncentric experience. Clin Ter. 2011; 162(5): 413-417.
18. Rozzi A, Salerno M. Bulding a simple way of knowledge in palliative care. Journal of Palliative care and Medicine. 2012. doi: 10.4172/2165-7386.1000e110
19. Bossi P, Kornek G, Lanzetta G, et al. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head Neck. 2012. doi: 10.1002/hed.23170
20. Rozzi AM. Palliative radiotherapy for terminally-ill cancer patients lack of usefulness or lack of knowledge. Journal of Palliative care and Medicine. 2012; 27: 1-2. doi: 10.4172/2165-7386.1000e121
20. Del FE, Dev R, Cabanillas ME, et al. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother. 2012; 24(4): 221-225. doi: 10.1179/1973947812Y.0000000022
21. Rozzi A, Lanzetta G. Palliative surgery and palliative medicine are we following the same fundamental principles. Journal of Palliative care and Medicine. 2013; 31: 1-2. doi: 10.4172/2165-7386.1000136
22. Rozzi A, Santini D, Salerno M, et al. Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract results of a phase II study. Med Oncol. 30(1): 407. doi: 10.1007/s12032-012-0407-5